Clinical Study on Robot Assisted Stereotactic Puncture Combined with Umbilical Cord Blood Mononuclear Cell Transplantation for the Treatment of Hypertensive Cerebral Hemorrhage

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073988

Enrollment

Unknown

Registered

2023-07-26

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage

Interventions

Control group:Robot assisted stereotactic puncture

Experimental group :Robot assisted stereotactic puncture combined with umbilical cord blood mononucle

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years old; (2) The brain CT scan confirmed cerebral hemorrhage in the basal ganglia region, which is in line with the surgical indications and timing of cerebral hemorrhage surgery; (3) Patients with subarachnoid hemorrhage require CTA examination to identify vascular malformations or aneurysms; (4) Individuals without severe cardiac and pulmonary dysfunction, able to tolerate general anesthesia; (5) The subjects or their guardians voluntarily sign the informed consent form for clinical trials; (6) Blood glucose 2.78-22.2 mmol, INR = 3, PT = 2 times normal value, PLT = 30 * 10 ^ 9/L.

Exclusion criteria

Exclusion criteria: (1) Within 90 days prior to the onset of the disease, there was severe head injury with residual neurological deficits; (2) Clear evidence suggests that bleeding is caused by cerebral aneurysms, arteriovenous malformations, traumatic brain injury, or tumor stroke; (3) Severe edema, obvious midline displacement, existing or at risk of cerebral hernia; (4) Progressive exacerbation of consciousness disorders, with CT examination indicating a progressive increase in hematoma volume; (5) Patients with heart and lung dysfunction who cannot tolerate general anesthesia. (6) Suffering from neurological and psychiatric disorders that may affect the assessment of neurological function, co infected patients, malignant tumors, or hematological disorders.

Design outcomes

Primary

Measure	Time frame
national institute of health stroke scale,NIHSS;	—

Secondary

Measure	Time frame
Barthel index;Fugl-Meyer;Function independent measure;	—

Countries

China

Contacts

Public ContactZhongchen Li

Liaocheng People's Hospital

lizhongchen1228@126.com+86 153 1416 5726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026